Rodriguez, Steve
Hug, Clemens http://orcid.org/0000-0002-8299-3274
Todorov, Petar http://orcid.org/0000-0003-4835-0643
Moret, Nienke http://orcid.org/0000-0001-6038-6863
Boswell, Sarah A. http://orcid.org/0000-0002-3118-3378
Evans, Kyle
Zhou, George http://orcid.org/0000-0002-1345-2634
Johnson, Nathan T. http://orcid.org/0000-0002-2952-6730
Hyman, Bradley T. http://orcid.org/0000-0002-7959-9401
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Albers, Mark W. http://orcid.org/0000-0001-7855-3455
Sokolov, Artem http://orcid.org/0000-0002-8056-0504
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG058063)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54- CA225088-02S1)
Article History
Received: 15 May 2020
Accepted: 21 January 2021
First Online: 15 February 2021
Competing interests
: The authors declare the following competing interests. P.K.S. is a member of the SAB or Board of Directors of Applied Biomath, RareCyte, NanoString and Glencoe Software and has equity in some of these companies. In the last 5 years, the Sorger lab has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships are directly or indirectly related to the content of this manuscript. B.T.H. has stock in Novartis and Dewpoint. N.T.J. is an employee of H3 Biomedicine, a subsidiary of Eisai Inc. that develops therapies for Alzheimer’s. S.R., P.K.S., M.W.A., and A.S. are inventors on a patent application (WO/2017/173451) for novel targets in neurodegenerative diseases. All other authors (C.H., P.T., N.M., S.B., K.E., G.Z.) declare no competing interests.